The health insurers say $140 million in losses since the start of the year are the result of an expensive new hepatitis C drug and a surge of nearly 190,000 new members assigned to the companies by MassHealth, the state Medicaid program. State health officials tell The Boston Globe (http://bit.ly/1oYZRpp ) that their data analysis does not corroborate all of the insurers' claims, but they are expected this week to propose higher reimbursement rates to the insurers for the fiscal year starting Oct.